Navigation Links
OrbusNeich Announces Availability of Azule™ Cobalt Chromium Stent
Date:3/14/2011

HONG KONG, March 14, 2011 /PRNewswire/ -- OrbusNeich today announced the launch of the CE marked Azule Cobalt Chromium Stent.  The Azule Stent combines the proven stent design of its predecessor, the company's Blazer™ Cobalt Chromium Stent, with a delivery system with enhanced crossability and flexible deliverability.

Azule features OrbusNeich's unique Dual Helix stent design, offering conformability and radial strength on thin, flexible and low-profile cobalt chromium stent struts.  The stent's tip length has been reduced from 5 mm to 4.25 mm, improving deliverability and crossability.  The precise laser forming of the tip results in a lower lesion entry profile, and the controlled laser welding of the balloon to the catheter improves the stent's trackability and flexibility.

"Continuous technology advancement is mandated by our customers and the very nature of interventional cardiology," said Al Novak, OrbusNeich's Chairman and CEO.  "We believe the underlying deliverability of a stent is, and will continue to be, a critically important factor that we strive to improve."

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous™ Stent, as well as other stents and balloons marketed under the names of Azule, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo™ Bio-engineered Sirolimus Eluting Stent, or Combo Stent, which combines the Genous pro-healing technology for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Subject of Sessions on Innovation at TCT 2007
3. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
4. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
5. Clinical Impact of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
6. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
7. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
8. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
9. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
10. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
11. Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  China Nepstar Chain ... a leading retail drugstore chain in China ... stores, today announced the resignation of Mr. Fuxiang ... personal reasons, effective immediately. Ms. Rebecca Yingnan Zhang ... the Company,s board of directors, effective immediately. Meanwhile, Ms. ...
(Date:5/21/2015)... DUBLIN , May 21, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/5x377m/north_american ) has announced the addition of ... by Type (Ankle Replacement, Digit Replacement, Elbow ... - Forecast to 2019" report to ... market for knee replacement was valued at ...
(Date:5/21/2015)... CHICAGO , May 21, 2015 /PRNewswire-USNewswire/ ... lump along the side of his neck, ... and took a couple weeks off from ... didn,t go away.                               ... Rendino, 26, was referred to Michel ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4
... LONDON and MISSISSAUGA, Ontario, March 29, 2011 GlaxoSmithKline ... VRX ) (TSX: VRX) announced today that the European ... an adjunctive (add-on) treatment of partial onset seizures (a ... specific area in one side of the brain), with ...
... TALLAHASSEE, Fla., March 29, 2011 Public/Private Sector Strategies ... Florida Senate President Mike Haridopolos, R-Melbourne, its report detailing ... The report makes recommendations in 21 areas that conservatively ... year. "Our charge was to identify steps ...
Cached Medicine Technology:GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 2GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 3GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 4GSK and Valeant Receive European Authorisation for Trobalt (retigabine) 5Senate Receives Rx Blueprint Plan That Reduces Spending and Increases Quality 2
(Date:5/22/2015)... A Phase 3 French study, ... of Clinical Oncology (ASCO)’s annual meeting at the ... those patients who received bevacizumab in addition to ... (Avastin® Genentech, Inc.) is an antibody that blocks ... routinely used to treat many other cancers, including ...
(Date:5/22/2015)... Wimbledon Health Partners, the leading on-site diagnostic ... NCV testing , is proud to announce the ... National athlete, to the Wimbledon Athletics division. , ... of testing and information it provides to be extremely ... this way they can focus on the task at ...
(Date:5/22/2015)... 2015 DMG Productions announces the upcoming ... broadcast on Friday, May 29, 2015 at 7:30 a.m. ... In this episode Innovations will explore Interstate Restoration, a ... quickly through disaster recovery and restoration. , Additionally, the ... collaboratively to develop and deliver training and education in ...
(Date:5/22/2015)... 2015 Ticket Down is a reputable source ... NHL Eastern Conference Finals Tickets . All seating for ... in the ticket listing. , For the first time ... top of the Eastern Conference. One of the original franchises ... ups and downs over the years, but the excitement level ...
(Date:5/22/2015)... 2015 In an effort to support ... is offering to donate $5 dollars for every maintenance ... or water softening system. Customers have their needs serviced, ... gets business; and the Special Olympics receives money. Hence ... helps over 4.4 million athletes, and boasts a myriad ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 3Health News:Parker and Sons is Proud to Support the Special Olympics with Their Everybody Wins Program 2
... of have mapped all the genes in a second type ... basic cell biology and the development of cancer.A team of ... of the charity Cancer Research UK has sequenced the genome ... genome// was mapped. ,Fifty of the 4,000 genes in ...
... in the brain responsible for imitation may be behind ,the ... searching for ,roots of empathy have now found brain regions ... network of brain regions that are involved in human imitation ... the self from others.// , ...
... for calcium flow in heart cells can help failing ... day replace mechanical-assist devices or heart transplants as an ... Dr. Roger Hajjar said many heart experts believe// that ... the elderly. Specifically, Hajjar and others hypothesized that abnormal ...
... to drought has shown there is a chemical link between ... Steven J. Neill and colleagues, from the University of the ... oxide — which facilitates erections in humans — also helps ... regulate// the plant's loss of water and keep it from ...
... researchers have identified a gene which allows the malaria ... a single-celled organism which is transmitted to humans ... evaded control efforts by building resistance to virtually all ... hoped that the new discovery will lead to a ...
... turn into every single tissue in the body has been ... could do this. Work is in the embryo stage but ... into tissues such as muscle, cartilage and brain cells, which ... Lemischka of the US's Princeton University said: "The work is ...
Cached Medicine News:Health News:Innovative yeast genome may handle Cancer Clues 2Health News:Gene treatment maintains normal Heart Beat 2
For the determination of urea nitrogen in human serum....
Intended for the quantitative determination of urea nitrogen in serum. Reaction: kinetic. Wavelength: 340 nm. Linearity: 150 mg/dL (53.4 mmol/L urea) at 37C....
Intended for the quantitative determination of total bilirubin in serum. Modified evelynmalloy method. Endpoint reaction. Wavelength: 555 nm. Linearity: 20 mg/dl (340 mol/l)...
... first microplate spectrophotometer designed specifically to run ... week. With rugged hardware, proven optical performance ... barrier of traditional spectrophotometry to obtain results ... easily read up to eight, 1 cm ...
Medicine Products: